Eisai (OTCMKTS:ESALY) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday.
According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “
Shares of Eisai (ESALY) opened at $59.28 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.81 and a current ratio of 2.18. The company has a market capitalization of $17,304.69, a P/E ratio of 61.75 and a beta of -0.25. Eisai has a one year low of $50.31 and a one year high of $63.06.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades Eisai (ESALY) to Hold” was published by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://baseballnewssource.com/markets/zacks-investment-research-upgrades-eisai-esaly-to-hold/1822104.html.
Eisai Co, Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company’s businesses include pharmaceutical business and other business. The Company’s segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South America), China, Asia (South Korea, Taiwan, Hong Kong, India and ASEAN), EMEA (Europe, the Middle East, Africa and Oceania) and Consumer Healthcare Business-Japan.
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with our FREE daily email newsletter.